Recent Finacing
Recent Raise
DecImmune Therapeutics develops monoclonal antibodies targeting the N2 neoepitope to inhibit innate immune–mediated tissue damage and preserve organ function, advancing a myocardial salvage program through preclinical/IND-enabling studies.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors